PetVivo Holdings, Inc. SEC Filings

Lai John reported acquisition or exercise transactions in this Form 4 filing.

PetVivo Holdings, Inc. reported that Chief Executive Officer John Lai, through a corporation he owns, received a grant of 75,000 shares of restricted common stock on July 21, 2026 at $0.77 per share as compensation for past performance, increasing his indirectly held common stock to 2,381,913 shares.

PetVivo Holdings, Inc. files its annual report describing an emerging veterinary medical device business built around Spryng, an injectable joint treatment for osteoarthritic dogs and horses. The company reported an approximate $10 million net loss for the year ended March 31, 2026 and an accumulated deficit of about $102.0 million.

Liquidity is a key concern: cash and cash equivalents were roughly $201,000 as of March 31, 2026, which management expects to fund operations for about one month, or roughly four months if up to $1.5 million is invested under an existing purchase option. As of June 29, 2026, non‑affiliate common stock had an aggregate market value of $12,126,991, with 37,594,245 shares outstanding. The report emphasizes dependence on Spryng, new distribution relationships with Vedco and Clipper, an exclusive licensing deal for VetStem’s PrecisePRP, and a portfolio of patents, trade secrets, and trademarks. Extensive risk factors highlight continuing losses, financing needs, prior Nasdaq delisting and trading on OTCQX, strong competition in animal health, manufacturing and distribution risks, and cybersecurity oversight processes.

PetVivo Holdings has signed an Agreement and Plan of Merger to acquire PiezoBioMembrane, Inc. (PBM) in an all‑stock transaction. PBM will merge into a PetVivo subsidiary and, after closing, operate as a wholly owned subsidiary of Cosmeta Corp., PetVivo’s biomaterials-focused operating arm.

PBM shareholders are slated to receive an aggregate of 3,000,000 shares of PetVivo restricted common stock. A first block of up to 1,500,000 shares will be fully vested at closing, while the remaining “Milestone Shares” will be issued but subject to forfeiture unless specified development and regulatory milestones are achieved.

Before closing, PBM must clear defined liabilities and convert or settle all preferred stock, SAFEs, options, warrants and other securities. Closing also depends on PetVivo completing an equity financing with at least $5.0 million in gross proceeds. PBM’s extensive intellectual property portfolio will remain in PBM, and key PBM personnel are expected to stay involved through consulting and service arrangements.

PetVivo Holdings, Inc. major holder A.L. Sarroff Fund, LLC reported open-market purchases tied to unit financing. The fund bought 187,500 shares of Common Stock and 187,500 Warrants, with each Unit priced at $0.80 and consisting of one share plus one Warrant.

The Warrants allow purchase of 187,500 shares of Common Stock at an exercise price of $1.10 per share until June 9, 2036. Following the transactions, the fund holds 10,439,729 shares of Common Stock and 187,500 Warrants directly, indicating a modest incremental increase in its position.

A.L. Sarroff Fund, LLC, a 10% owner of PetVivo Holdings, Inc., reported a bona fide gift transfer of 200,000 shares of common stock on May 28, 2026. The transfer was recorded at $0.00 per share, and the fund now directly holds 10,252,229 shares. Alan L. Sarroff, as Chief Executive Officer and Managing Member of the fund, is deemed to beneficially own these securities with sole voting and dispositive power.

PetVivo Holdings, Inc. saw its significant shareholder A.L. Sarroff Fund, LLC make an open-market purchase of common stock. On May 22, 2026, the fund bought 250,000 shares at 0.40 per share, increasing its direct holdings to 10,452,229 shares.

Alan L. Sarroff, as Chief Executive Officer and Managing Member of A.L. Sarroff Fund, is deemed to beneficially own these securities and to have sole voting and dispositive power over them. This transaction modestly increases an already large position in the company.

PetVivo Holdings, Inc. reported that its Chief Financial Officer, Garry N. Lowenthal, indirectly acquired 66,421 shares of common stock as a grant of restricted stock. The award was made to a corporation owned by him as compensation for his past performance at an implied price of $0.72 per share.

Following this grant, the filing shows 878,881 shares of common stock held indirectly through the corporation. This is a compensation-related, non-market transaction rather than an open-market purchase or sale.

Lai John reported acquisition or exercise transactions in this Form 4 filing.

PetVivo Holdings, Inc. reported that a corporation owned by Chief Executive Officer John Lai received a grant of restricted common stock as compensation for his past performance. The award covers 66,421 shares of common stock at a stated value of $0.72 per share.

Following this grant, the corporation associated with Lai holds 2,306,913 shares of PetVivo common stock indirectly. This is a compensation-related stock award rather than an open-market purchase or sale, and reflects additional equity granted to an entity affiliated with the CEO.

Rudelius Robert James reported acquisition or exercise transactions in this Form 4 filing.

PetVivo Holdings director Robert James Rudelius purchased 50,000 shares of restricted common stock in a private sale. On April 15, 2026, he bought these shares from another PetVivo shareholder at $0.40 per share, bringing his direct holdings to 403,392 common shares. He also reports indirect ownership of 21,000 common shares held by a corporation.